Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2014 · 10-Q
Revenue$0.00$0.00— vs Q2 2013 Net Income-$1.63M-$1.63MN/M vs Q2 2013 EPS Diluted-$0.03-$0.03N/M vs Q2 2013 Operating Income-$1,636,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$3,111,000— ended Dec 31, 2013 · filed Feb 14, 2014 · 45 d after period end